Company Filing History:
Years Active: 1988-1989
Title: Vera Morhenn: Innovator in Monoclonal Antibody Research
Introduction
Vera Morhenn is a distinguished inventor based in Palo Alto, CA, known for her significant contributions to the field of biomedical research. She holds 2 patents that focus on innovative methods for detecting malignant cells, particularly in skin and cervical conditions. Her work has the potential to greatly enhance diagnostic techniques in oncology.
Latest Patents
One of her latest patents is titled "Monoclonal antibody specific for human basal cell surface antigen." This invention involves novel monoclonal antibodies that target a specific antigenic site on proteins characteristic of human basal cells and malignant squamous cells. Importantly, these antibodies do not bind to mesenchymal cells such as fibroblasts and endothelial cells. The protein on the cell surface that binds to one of the antibodies has a molecular weight of approximately 120,000, as determined by one-dimensional gel electrophoresis. These antibodies are particularly useful in diagnostic methods for detecting malignant cells, such as identifying residual tumor cells in skin subjected to microscopically-controlled surgery.
Another significant patent is the "Method for determining the presence of malignant cells." This invention outlines a method for identifying malignant conditions at a specific locus by using an exfoliative cell specimen. The specimen is contacted with an antibody that is specific for an antigenic site typically found only when a malignant condition is present. The binding of the antibody to the antigenic site is observed, which correlates with the presence of a malignant condition. This method has practical applications, such as in the detection of cervical carcinoma.
Career Highlights
Vera Morhenn has worked with notable companies in the field, including Syntex Inc. and Syntex LLC. Her experience in these organizations has contributed to her expertise in monoclonal antibody research and development.
Collaborations
Throughout her career, Vera has collaborated with esteemed colleagues, including Anthony C. Allison and Alain B. Schreiber. These collaborations have further enriched her research and innovations in the field.
Conclusion
Vera Morhenn's contributions to monoclonal antibody research and her innovative patents have the potential to significantly impact the field of diagnostics in oncology. Her work exemplifies the importance of innovation in improving medical outcomes.